[1]
|
Hou X, Shen G, Zhou L, et al. Artificial Intelligence in Cervical Cancer Screening and Diagnosis[J]. Front Oncol, 2022, 12: 851367. doi: 10.3389/fonc.2022.851367 |
[2]
|
Bao H, Sun X, Zhang Y, et al. The artificial intelligence-assisted cytology diagnostic system in large-scale cervical cancer screening: A population-based cohort study of 0.7 million women[J]. Cancer Med, 2020, 9: 6896-6906. doi: 10.1002/cam4.3296 |
[3]
|
Hussain E, Mahanta LB, Borah H, et al. Liquid based-cytology Pap smear dataset for automated multi-class diagnosis of pre-cancerous and cervical cancer lesions[J]. Data Brief, 2020, 30: 105589. doi: 10.1016/j.dib.2020.105589 |
[4]
|
Bao H, Bi H, Zhang X, et al. Artificial intelligence-assisted cytology for detection of cervical intraepithelial neoplasia or invasive cancer: A multicenter, clinical-based, observa-tional study[J]. Gynecol Oncol, 2020, 159: 171-178. |
[5]
|
Wilbur DC, Nayar R. Bethesda 2014: improving on a paradigm shift[J]. Cytopathology, 2015, 26: 339-342. doi: 10.1111/cyt.12300 |
[6]
|
Heider A, Austin RM, Zhao C. HPV test results stratify risk for histopathologic follow-up findings of high-grade cervical intra-epithelial neoplasia in women with low-grade squamous intra-epithelial lesion Pap results[J]. Acta Cytol, 2011, 55: 48-53. doi: 10.1159/000320877 |
[7]
|
Levi AW, Harigopal M, Hui P, et al. Use of high-risk human papillomavirus testing in patients with low-grade squamous intraepithelial lesions[J]. Cancer Cytopathol, 2011, 119: 228-234. doi: 10.1002/cncy.20172 |
[8]
|
Thrall MJ, Smith DA, Mody DR. Women > or=30 years of age with low grade squamous intraepithelial lesion (LSIL) have low positivity rates when cotested for high-risk human papillomavirus: should we reconsider HPV triage for LSIL in older women?[J]. Diagn Cytopathol, 2010, 38: 407-412. doi: 10.1002/dc.21209 |
[9]
|
Özcan Z, Kimiloğlu E, Iğdem AA, et al. Comparison of the Diagnostic Utility of Manual Screening and the ThinPrep Imaging System in Liquid-Based Cervical Cytology[J]. Turk Patoloji Derg, 2020, 36: 135-141. |
[10]
|
Wright TC Jr, Stoler MH, Parvu V, et al. Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, >/=21years of age, with ASC-US or LSIL cytology[J]. Gynecol Oncol, 2019, 154: 360-367. doi: 10.1016/j.ygyno.2019.05.012 |
[11]
|
Eversole GM, Moriarty AT, Schwartz MR, et al. Practices of participants in the college of american pathologists interlaboratory comparison program in cervicovaginal cytology, 2006[J]. Arch Pathol Lab Med, 2010, 134: 331-335. doi: 10.5858/134.3.331 |
[12]
|
Harbhajanka A, Chahar S, Michael CW. The pathological outcome of ThinPrep Pap tests diagnosed as glandular cell abnormalities alone versus combined glandular and squamous abnormalities[J]. Diagn Cytopathol, 2019, 47: 88-93. doi: 10.1002/dc.24024 |
[13]
|
Zheng B, Austin RM, Liang X, et al. Bethesda System reporting rates for conventional Papanicolaou tests and liquid-based cytology in a large Chinese, College of American Pathologists-certified independent medical laboratory: analysis of 1394389 Papanicolaou test reports[J]. Arch Pathol Lab Med, 2015, 139: 373-377. doi: 10.5858/arpa.2014-0070-OA |
[14]
|
Amaral RG, Zeferino LC, Hardy E, et al. Quality assurance in cervical smears: 100% rapid rescreening vs. 10% random rescreening[J]. Acta Cytol, 2005, 49: 244-248. doi: 10.1159/000326144 |
[15]
|
Tavares SB, de Souza NL, Manrique EJ, et al. Internal quality control for cervical cytopathology: comparison of potential false-negatives detected at rapid prescreening and at 100% rapid review[J]. Acta Cytol, 2014, 58: 439-445. doi: 10.1159/000368041 |